A third option could be that tumors with high expression of HER-2, as it is the case with progressed castrate resistant prostate cancer [3–5], are often characterized by alleviated capacity of being recognized by tumor antigen-specific CTL. This evidence concerns the gene ERBB2 and prostate cancer.